Inherited retinal diseases (IRDs) represent a significant challenge, often leading to progressive vision loss and blindness, with symptoms frequently emerging in childhood. For patients and families navigating these conditions, the prospect of effective treatments has long been a beacon of hope. Recent advancements in research and drug delivery technologies are bringing us closer to therapies that could significantly alter the course of these debilitating diseases.
Sustained Drug Delivery Targets Pediatric IRDs
A groundbreaking collaboration between PolyActiva and RareSight is focusing on developing first-in-class pharmacologic treatments specifically for rare pediatric IRDs. Many IRDs begin early in life, and while they slowly erode vision, there are currently no approved drug therapies to halt or slow the damage. This partnership aims to change that by leveraging PolyActiva's PREZIA drug delivery platform.
The PREZIA platform utilizes covalent bonding to attach therapeutic agents to a polymer backbone, allowing for sustained, consistent drug release directly to retinal tissue after intravitreal administration. This innovative approach is designed to bypass the blood-retina barrier, providing continuous and precise drug exposure while minimizing systemic side effects. A key benefit of this sustained-release implant is the potential to reduce the burden of frequent dosing, which is particularly challenging for children and their caregivers. The goal is to develop new chemical entity (NCE)-eligible pro-drug candidates that can maintain consistent therapeutic exposure over extended periods, potentially ranging from one week to over a year, without the need for daily administration. PolyActiva's PREZIA platform is also biodegradable, eliminating residual buildup and supporting repeat dosing.
A Strategy to Prevent Blindness by Managing Misfolded Proteins
In a separate but equally promising area of research, scientists at Duke University have explored a strategy to prevent blindness by addressing the issue of misfolded proteins in retinal cells. Many inherited retinal conditions, such as retinitis pigmentosa, are caused by gene mutations that lead to the creation of misfolded proteins. These proteins accumulate inside eye cells, ultimately causing their death.
Duke scientists demonstrated in mice that boosting the cells' ability to process these misfolded proteins could prevent their aggregation and significantly delay the onset of blindness. The research, outlined in Nature Communications, focused on the proteasome, the cellular machinery responsible for eliminating misfolded proteins. By genetically increasing the quantity of